uric acid has been researched along with Fabry Disease in 2 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
Fabry Disease: An X-linked inherited metabolic disease caused by a deficiency of lysosomal ALPHA-GALACTOSIDASE A. It is characterized by intralysosomal accumulation of globotriaosylceramide and other GLYCOSPHINGOLIPIDS in blood vessels throughout the body leading to multi-system complications including renal, cardiac, cerebrovascular, and skin disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We herein report a Fabry disease patient with enzyme replacement therapy (ERT)-resistant proteinuria who showed improvement in the estimated glomerular filtration rate (eGFR) decline rate after uric acid (UA)-lowering therapy." | 8.12 | Improvement in Decline Rate of Estimated Glomerular Filtration Rate after Febuxostat Treatment in a Fabry Disease Patient with Enzyme Replacement Therapy-resistant Proteinuria. ( Chin-Kanasaki, M; Imamura-Uehara, Y; Kato, K; Kume, S; Kuwagata, S; Maegawa, H; Nakagawa, Y; Ohno, S; Takeda, N; Yamahara, K; Yasuda-Yamahara, M, 2022) |
| " We herein report a Fabry disease patient with enzyme replacement therapy (ERT)-resistant proteinuria who showed improvement in the estimated glomerular filtration rate (eGFR) decline rate after uric acid (UA)-lowering therapy." | 4.12 | Improvement in Decline Rate of Estimated Glomerular Filtration Rate after Febuxostat Treatment in a Fabry Disease Patient with Enzyme Replacement Therapy-resistant Proteinuria. ( Chin-Kanasaki, M; Imamura-Uehara, Y; Kato, K; Kume, S; Kuwagata, S; Maegawa, H; Nakagawa, Y; Ohno, S; Takeda, N; Yamahara, K; Yasuda-Yamahara, M, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kume, S | 1 |
| Yasuda-Yamahara, M | 1 |
| Imamura-Uehara, Y | 1 |
| Kuwagata, S | 1 |
| Yamahara, K | 1 |
| Takeda, N | 1 |
| Chin-Kanasaki, M | 1 |
| Kato, K | 1 |
| Ohno, S | 1 |
| Nakagawa, Y | 1 |
| Maegawa, H | 1 |
| Rob, D | 1 |
| Marek, J | 1 |
| Dostálová, G | 1 |
| Goláň, L | 1 |
| Linhart, A | 1 |
2 other studies available for uric acid and Fabry Disease
| Article | Year |
|---|---|
Improvement in Decline Rate of Estimated Glomerular Filtration Rate after Febuxostat Treatment in a Fabry Disease Patient with Enzyme Replacement Therapy-resistant Proteinuria.
Topics: Adult; alpha-Galactosidase; Enzyme Replacement Therapy; Fabry Disease; Febuxostat; Glomerular Filtra | 2022 |
Uric Acid as a Marker of Mortality and Morbidity in Fabry Disease.
Topics: Adult; Biomarkers; Disease Progression; Fabry Disease; Female; Follow-Up Studies; Humans; Ischemic A | 2016 |